BioCryst Pharmaceuticals, Inc. (BCRX) - NASDAQ
  • Wed, May 18, 2:44 AM
    • More than three months after President Obama asked for $1.8B in emergency funds to combat the Zika virus, the Senate took its first step to approve the request by passing a compromise $1.1B measure.
    • At the same time, the White House issued a veto threat against a House Republicans' bill that would provide only $622M, a figure the White House called "woefully inadequate" to fight the rapidly spreading disease.
    • Related tickers: SNY, INO, AEMD, XON, CEMI, BCRX, TMO, OTCQB:GOVX
    | Wed, May 18, 2:44 AM | 22 Comments
  • Thu, May 5, 10:53 AM
    • BioCryst Pharmaceuticals (BCRX -15.7%) Q1 results: Revenues: $4.8M (-29.4%); R&D Expense: $3.2M (-22.0%); SG&A: $20.6M (+20.5%); Operating Loss: ($19M) (-31.9%); Net Loss: ($22.8M) (-50.0%); Loss Per Share: ($0.31) (-47.6%); Quick Assets: $77M (-22.4%).
    • 2016 Guidance: Net operating cash use: $55M - 75M (unch); Operating Expenses: $78M - 98M (unch).
    | Thu, May 5, 10:53 AM
  • Thu, May 5, 6:45 AM
    • BioCryst Pharmaceuticals (NASDAQ:BCRX): Q1 EPS of -$0.31 misses by $0.08.
    • Revenue of $4.82M (-29.4% Y/Y) misses by $0.6M.
    • Press Release
    | Thu, May 5, 6:45 AM
  • Wed, May 4, 5:30 PM
  • Thu, Apr. 14, 2:43 AM
    • U.S. health authorities have finally concluded that infection with the Zika virus in pregnant women is a cause of birth defects and other severe brain abnormalities in babies.
    • "There isn't any doubt that Zika causes microcephaly," said Tom Frieden, director of the U.S. Centers for Disease Control and Prevention.
    • The mosquito-born disease was assumed to be responsible for the alarming rise in birth defects among the Zika-hit areas of Brazil, but it had not been declared as the definitive cause until now.
    • Related tickers: SNY, INO, AEMD, XON, CEMI, BCRX, TMO, OTCQB:GOVX
    | Thu, Apr. 14, 2:43 AM | 13 Comments
  • Tue, Apr. 12, 2:36 AM
    • Dr. Anne Schuchat, a deputy director of the Centers for Disease Control and Prevention, told reporters the type of mosquito in which the virus is carried is present in a wider number of U.S. states, calling the revelation "scarier than we thought."
    • Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, announced at a White House briefing that the first Zika vaccine candidate should be available in September.
    • Related tickers: SNY, INO, AEMD, XON, CEMI, BCRX, TMO, OTCQB:GOVX
    | Tue, Apr. 12, 2:36 AM | 14 Comments
  • Thu, Mar. 31, 3:07 AM
    • Two mosquito species that carry the dangerous Zika virus may inhabit a wider range of North America than previously thought.
    • A new study published in the New England Journal of Medicine shows the potential range of the Aedes aegypti mosquito blanketing the southern U.S. and reaching as far north as San Francisco, Kansas City, and NYC.
    • The likely extent of another Zika-carrying mosquito species, Aedes albopictus, stretches across the Southwest and covers most of the eastern U.S., including northern New England, according to a study by the CDC.
    • Related tickers: SNY, INO, AEMD, XON, CEMI, BCRX, TMO, OTCQB:GOVX
    | Thu, Mar. 31, 3:07 AM | 11 Comments
  • Sun, Mar. 20, 11:05 AM
    • On an inexorable march across the hemisphere, the Zika virus has begun spreading through Puerto Rico, now the United States' front line in a looming epidemic.
    • A quarter of the island's 3.5M people will likely get the Zika virus within a year, according to the Centers for Disease Control and Prevention, and eventually 80% or more may be infected.
    • The territory's first Zika case was confirmed in December, and the governor declared a health emergency on Feb. 5.
    • Related tickers: SNY, INO, AEMD, XON, CEMI, BCRX, TMO, OTCQB:GOVX
    | Sun, Mar. 20, 11:05 AM | 20 Comments
  • Wed, Mar. 9, 2:20 AM
    • Sexual transmission of the Zika virus is more common than previously thought, according to the World Health Organization.
    • After a meeting of its emergency committee on Tuesday, the U.N. health agency said there was also increasing evidence that a spike in birth defects and neurological problems are caused by the disease.
    • Local transmission of Zika has now been reported in 31 countries across Latin America and the Caribbean.
    • Related tickers: SNY, INO, AEMD, XON, CEMI, BCRX, TMO, OTCQB:GOVX
    | Wed, Mar. 9, 2:20 AM | 6 Comments
  • Tue, Mar. 8, 9:17 AM
    | Tue, Mar. 8, 9:17 AM | 3 Comments
  • Mon, Mar. 7, 11:50 AM
    • Micro cap BioCryst Pharmaceuticals (BCRX +22.5%) is up on more than double normal volume in apparent response to its announcement of positive results in preclinical testing of its RNA antiviral candidate, BCX4430, in Zika-infected immune-deficient mice. The data will presented at a World Health Organization (WHO) meeting in Geneva, Switzerland, March 7 - 9.
    • BCX4430 was administered twice a day via intramuscular (IM) injection beginning four hours prior to virus challenge and continuing for eight days. In the standard dose group, 87.5% (n=7/8) survived through Day 28. In the low dose group, none survived (n=0/8) through the same time period. Overall survival for the standard dose of BCX4430 was superior to control and ribavirin.
    • BCX4430 is an RNA dependent-RNA polymerase inhibitor that has shown broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. Zika is a flavivirus.
    • The development of BCX4430 is being funded, in large part, by the U.S. Health and Human Services' BARDA (Biomedical Advanced Research and Development Authority) unit.
    • Previously: BioCryst Pharma snags advanced development project for RNA pathogens (March 31, 2015)
    | Mon, Mar. 7, 11:50 AM
  • Mon, Mar. 7, 9:11 AM
    | Mon, Mar. 7, 9:11 AM | 1 Comment
  • Tue, Feb. 23, 9:55 AM
    • BioCryst Pharmaceuticals (BCRX -2.8%) Q4 results: Revenues: $4.6M (-14.8%); R&D Expense: $19M (+2.7%); SG&A: $2.7M (+35.0%); Operating Loss: ($17.2M) (-13.2%); Net Loss: ($18.1M) (-54.7%); Loss Per Share: ($0.25) (-56.3%).
    • FY2015 results: Revenues: $48.3M (+255.1%); R&D Expense: $72.8M (+40.5%); SG&A: $13M (+73.3%); Operating Loss: ($39.4M) (+14.0%); Net Loss: ($43M) (+4.9%); Loss Per Share: ($0.59) (+13.2%); Quick Assets: $99.2M (-12.9%).
    • 2016 Guidance: Net operating cash use: $55M - 75M; Operating Expenses: $78M - 98M.
    | Tue, Feb. 23, 9:55 AM
  • Tue, Feb. 23, 6:52 AM
    • BioCryst Pharmaceuticals (NASDAQ:BCRX): Q4 EPS of -$0.25 beats by $0.01.
    • Revenue of $4.6M (-15.6% Y/Y) misses by $1.74M.
    • Press Release
    | Tue, Feb. 23, 6:52 AM
  • Mon, Feb. 22, 5:30 PM
    | Mon, Feb. 22, 5:30 PM | 10 Comments
  • Fri, Feb. 12, 7:38 AM
    • Gilead Sciences (NASDAQ:GILD) initiated with Outperform rating and $120 (37% upside) price target by Oppenheimer.
    • CareDx (NASDAQ:CDNA) initiated with Buy rating and $12 (137% upside) price target by Janney Capital.
    • Shire plc (NASDAQ:SHPG) initiated with Neutral rating by Guggenheim.
    • Ultragenyx Pharmaceutical (NASDAQ:RARE) initiated with Buy rating and $104 (95% upside) price target by H.C. Wainwright.
    • Depomed (NASDAQ:DEPO) initiated with Buy rating and $22 (38% upside) price target by UBS.
    • ACADIA Pharmaceuticals (NASDAQ:ACAD) initiated with Buy rating and $40 (128% upside) price target by Bank of America.
    • Leerink restarts coverage on eight stocks: four Outperforms: Alexion Pharmaceuticals (NASDAQ:ALXN); Regeneron Pharmaceuticals (NASDAQ:REGN); Vertex Pharmaceuticals (NASDAQ:VRTX) and Gilead Sciences (GILD); four Market Performs: Celgene (NASDAQ:CELG); Biogen (NASDAQ:BIIB); Medivation (NASDAQ:MDVN) and Amgen (NASDAQ:AMGN).
    • TESARO (NASDAQ:TSRO) initiated with Buy rating by Lake Street.
    • AbbVie (NYSE:ABBV) initiated with Outperform rating by William Blair.
    • Seattle Genetics (NASDAQ:SGEN) upgraded to Buy with $38 (41% upside) price target by Cantor Fitzgerald.
    • Shire plc (SHPG) upgraded to Outperform with price target of $240 (59% upside) by RBC.
    • Amedisys (NASDAQ:AMED) upgraded to Outperform with $40 (15% upside) price target by Oppenheimer.
    • Smith & Nephew (NYSE:SNN) downgraded to Neutral from Buy by UBS. Price target lowered to 1,100p (4% upside) from 1,250p.
    • Quidel (NASDAQ:QDEL) downgraded to Hold from Buy by Canaccord. Price target lowered to $18 (18% upside) from $22.
    • BioCryst Pharmaceuticals (NASDAQ:BCRX) downgraded Neutral from Overweight by JP Morgan. Price target lowered to $5 (201% upside) from $16.
    | Fri, Feb. 12, 7:38 AM | 11 Comments
Company Description
BioCryst Pharmaceuticals, Inc. is a biotechnology company that designs, optimizes and develops novel drugs that block key enzymes involved in the pathogenesis of diseases with its focus on therapeutic areas with unmet medical needs. It integrates the disciplines of biology, crystallography,... More
Sector: Healthcare
Industry: Biotechnology
Country: United States